MA26714A1 - Composes nouveaux modulateurs de chimiokine ccr5 et compositions pharmaceutiques les contenant - Google Patents

Composes nouveaux modulateurs de chimiokine ccr5 et compositions pharmaceutiques les contenant

Info

Publication number
MA26714A1
MA26714A1 MA25868A MA25868A MA26714A1 MA 26714 A1 MA26714 A1 MA 26714A1 MA 25868 A MA25868 A MA 25868A MA 25868 A MA25868 A MA 25868A MA 26714 A1 MA26714 A1 MA 26714A1
Authority
MA
Morocco
Prior art keywords
chimiokine
novel
pharmaceutical compositions
compositions containing
ccr5 modulators
Prior art date
Application number
MA25868A
Other languages
English (en)
Inventor
Anthony Price David
Luzia Christa Stammen Blanda
Perros Manoussos
Robert Armour Duncan
Wood Anthony
Paul Edwards Martin
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9828420.1A external-priority patent/GB9828420D0/en
Priority claimed from GBGB9921375.3A external-priority patent/GB9921375D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of MA26714A1 publication Critical patent/MA26714A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/08—Bridged systems
MA25868A 1998-12-23 1999-12-22 Composes nouveaux modulateurs de chimiokine ccr5 et compositions pharmaceutiques les contenant MA26714A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9828420.1A GB9828420D0 (en) 1998-12-23 1998-12-23 CCR5 antagonists useful as anti-hiv agents
GBGB9921375.3A GB9921375D0 (en) 1999-09-10 1999-09-10 CCR5 Modulators

Publications (1)

Publication Number Publication Date
MA26714A1 true MA26714A1 (fr) 2004-12-20

Family

ID=26314899

Family Applications (1)

Application Number Title Priority Date Filing Date
MA25868A MA26714A1 (fr) 1998-12-23 1999-12-22 Composes nouveaux modulateurs de chimiokine ccr5 et compositions pharmaceutiques les contenant

Country Status (48)

Country Link
US (1) US6586430B1 (fr)
EP (1) EP1140085B1 (fr)
JP (1) JP3602795B2 (fr)
KR (1) KR100425612B1 (fr)
CN (1) CN1331591A (fr)
AP (1) AP1697A (fr)
AR (1) AR024233A1 (fr)
AT (1) ATE505190T1 (fr)
AU (1) AU763644B2 (fr)
BG (1) BG65448B1 (fr)
BR (1) BRPI9917007B8 (fr)
CA (1) CA2350073C (fr)
CO (1) CO5300387A1 (fr)
CR (2) CR6392A (fr)
CU (1) CU23344A3 (fr)
CY (1) CY1111504T1 (fr)
CZ (1) CZ300926B6 (fr)
DE (1) DE69943352D1 (fr)
DK (1) DK1140085T3 (fr)
DZ (2) DZ2979A1 (fr)
EA (1) EA004988B1 (fr)
EE (1) EE05170B1 (fr)
EG (1) EG24400A (fr)
GC (1) GC0000117A (fr)
GE (1) GEP20033131B (fr)
HK (1) HK1039902A1 (fr)
HR (2) HRP20010468B1 (fr)
HU (1) HU228754B1 (fr)
ID (1) ID28965A (fr)
IL (2) IL143512A0 (fr)
IS (1) IS5944A (fr)
MA (1) MA26714A1 (fr)
ME (1) ME00513B (fr)
NO (1) NO330677B1 (fr)
NZ (1) NZ511794A (fr)
OA (1) OA11735A (fr)
PA (1) PA8487201A1 (fr)
PE (1) PE20001420A1 (fr)
PL (1) PL201875B1 (fr)
PT (1) PT1140085E (fr)
RS (1) RS51701B (fr)
SI (1) SI1140085T1 (fr)
SK (1) SK287020B6 (fr)
TN (1) TNSN99252A1 (fr)
TR (1) TR200101793T2 (fr)
TW (1) TW577888B (fr)
UA (1) UA72750C2 (fr)
WO (1) WO2000038680A1 (fr)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1013276A1 (fr) * 1998-12-23 2000-06-28 Pfizer Inc. Aminoazacycloalcanes comme modulateurs de CCR5
US7217714B1 (en) * 1998-12-23 2007-05-15 Agouron Pharmaceuticals, Inc. CCR5 modulators
US6248755B1 (en) 1999-04-06 2001-06-19 Merck & Co., Inc. Pyrrolidine modulators of chemokine receptor activity
US6399619B1 (en) 1999-04-06 2002-06-04 Merck & Co., Inc. Pyrrolidine modulators of chemokine receptor activity
SE9903544D0 (sv) 1999-10-01 1999-10-01 Astra Pharma Prod Novel compounds
EP1118858A3 (fr) * 2000-01-12 2003-07-09 Pfizer Limited Méthode d'essai
GB2359078A (en) 2000-02-11 2001-08-15 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
GB2359081A (en) 2000-02-11 2001-08-15 Astrazeneca Uk Ltd Pharmaceutically active thiazolopyrimidines
GB2359551A (en) 2000-02-23 2001-08-29 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
GB0005642D0 (en) * 2000-03-10 2000-05-03 Astrazeneca Uk Ltd Chemical compounds
US6667314B2 (en) * 2000-05-26 2003-12-23 Pfizer, Inc. Tropane derivatives useful in therapy
HU225810B1 (en) 2000-05-26 2007-10-29 Pfizer Therapeutically effective tropane derivatives, process for their preparation pharmaceutical compositions containing them and their use
GB0015562D0 (en) * 2000-06-23 2000-08-16 Pfizer Ltd Heterocycles
US6531484B2 (en) 2000-10-11 2003-03-11 Merck & Co., Inc. Pyrrolidine modulators of CCR5 chemokine receptor activity
US6511994B2 (en) 2000-10-11 2003-01-28 Merck & Co., Inc. Modulators of CCR5 chemokine receptor activity
SE0003828D0 (sv) 2000-10-20 2000-10-20 Astrazeneca Ab Novel compounds
WO2002051414A1 (fr) * 2000-12-22 2002-07-04 Takeda Chemical Industries, Ltd. Compositions médicinales s'administrant par voie orale
SE0101322D0 (sv) 2001-04-12 2001-04-12 Astrazeneca Ab Novel compounds
SE0103818D0 (sv) * 2001-11-15 2001-11-15 Astrazeneca Ab Chemical compounds
TW200305395A (en) * 2002-03-15 2003-11-01 Novartis Ag Organic compounds
GEP20074210B (en) * 2002-04-08 2007-10-10 Pfizer Tropane derivatives as ccr5 modulators
US6855724B2 (en) 2002-04-08 2005-02-15 Agouron Pharmaceuticals, Inc. Tropane derivatives useful in therapy
BR0309982A (pt) * 2002-05-23 2005-03-22 Pfizer Método para identificação de um ligando, pelo qual o tempo de residência no receptor é medido
GB0221828D0 (en) 2002-09-20 2002-10-30 Astrazeneca Ab Novel compound
US7202259B2 (en) * 2002-11-18 2007-04-10 Euro-Celtique S.A. Therapeutic agents useful for treating pain
US7759336B2 (en) * 2002-12-10 2010-07-20 Ono Pharmaceutical Co., Ltd. Nitrogen-containing heterocyclic compounds and medicinal use thereof
EP1569646A2 (fr) * 2002-12-13 2005-09-07 Smithkline Beecham Corporation Antagonistes de ccr5 utiles comme agents therapeutiques
US7569579B2 (en) 2002-12-13 2009-08-04 Smithkline Beecham Corporation Cyclopropyl compounds as ccr5 antagonists
AU2004220225B2 (en) 2003-03-14 2010-06-17 Ono Pharmaceutical Co., Ltd. Nitrogen-containing heterocyclic derivatives and drugs containing the same as the active ingredient
EP2364982A1 (fr) 2003-04-18 2011-09-14 ONO Pharmaceutical Co., Ltd. Dérivés de spiropipéridine comme antgonistes du recepteur chémokine et leur usage médical
JP2007500694A (ja) * 2003-07-31 2007-01-18 アストラゼネカ・アクチエボラーグ Ｃｃｒ５受容体モジュレーターとしてのピペリジン誘導体
US7220772B2 (en) 2003-09-05 2007-05-22 Pfizer, Inc. Pyrazole derivatives
CA2579609A1 (fr) 2003-09-10 2005-03-17 Virochem Pharma Inc. Composes de spirohydantoine et procedes de modulation de l'activite des recepteurs de chimiokine
US7309790B2 (en) * 2003-10-03 2007-12-18 Pfizer Inc Chemical compounds
GB0328243D0 (en) 2003-12-05 2004-01-07 Astrazeneca Ab Methods
JP4634401B2 (ja) * 2004-01-30 2011-02-16 ユーロ−セルティーク エス．エイ． ４−テトラゾリル−４−フェニルピペリジン化合物の製造方法
TW200533348A (en) 2004-02-18 2005-10-16 Theravance Inc Indazole-carboxamide compounds as 5-ht4 receptor agonists
MXPA06011884A (es) * 2004-04-14 2006-12-14 Pfizer Compuestos de imidazol unidos a azufre para el tratamiento del virus de inmunodeficiencia humana.
TW200610761A (en) * 2004-04-23 2006-04-01 Astrazeneca Ab Chemical compounds
PL1761542T3 (pl) 2004-06-09 2008-06-30 Hoffmann La Roche Pochodne oktahydropirolo[3,4-c]pirolu i ich zastosowanie jako środków przeciwwirusowych
RU2409565C2 (ru) 2004-09-13 2011-01-20 Оно Фармасьютикал Ко., Лтд. Азотистые гетероциклические производные и лекарственные средства, содержащие их в качестве активного ингредиента
MX2007012472A (es) * 2005-04-08 2007-12-06 Neurosearch As (+)-y-(-)-8-alquil-3-(trifluoralquilsulfoniloxi)-8-azabicicl (3.2.1)cot-2-eno.
US7462639B2 (en) 2005-04-14 2008-12-09 Hoffmann-La Roche Inc. Aminopyrazole derivatives
JPWO2006129679A1 (ja) 2005-05-31 2009-01-08 小野薬品工業株式会社 スピロピペリジン化合物およびその医薬用途
US7665658B2 (en) 2005-06-07 2010-02-23 First Data Corporation Dynamic aggregation of payment transactions
ES2277745B1 (es) * 2005-06-14 2008-06-01 Laboratorios Almirall S.A. Derivados n-amida de 8-azabiciclo /3.2.1/oct-3-ilo como antagonistas de ccr1.
PT1942108E (pt) 2005-10-28 2013-10-24 Ono Pharmaceutical Co Composto com um grupo básico e a sua utilização
EP1961744B1 (fr) 2005-11-18 2013-04-17 Ono Pharmaceutical Co., Ltd. Composé contenant un groupe basique et son utilisation
JPWO2007105637A1 (ja) 2006-03-10 2009-07-30 小野薬品工業株式会社 含窒素複素環誘導体およびそれらを有効成分とする薬剤
US20080015834A1 (en) * 2006-07-13 2008-01-17 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for molecular inhibition
US20080015833A1 (en) * 2006-07-13 2008-01-17 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for molecular inhibition of protein misfolding
US20080015787A1 (en) * 2006-07-13 2008-01-17 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for treating disease
US20090082344A1 (en) * 2006-07-13 2009-03-26 Searete Llc Methods and systems for treating disease
JP5245827B2 (ja) 2006-07-31 2013-07-24 小野薬品工業株式会社 スピロ結合した環状基を含有する化合物およびその用途
EP2121676A1 (fr) * 2006-12-19 2009-11-25 Auspex Pharmaceuticals, Inc. Préparation et utilité d'inhibiteurs de ccr5
EP2433937B1 (fr) * 2007-08-31 2016-06-29 Purdue Pharma LP Composés de pipéridine de type quinoxaline substituée et leurs utilisations
WO2010129351A1 (fr) 2009-04-28 2010-11-11 Schepens Eye Research Institute Procédé pour identifier et pour traiter une dégénérescence maculaire liée à l'âge
EP2456309B1 (fr) * 2009-07-24 2015-12-23 GlaxoSmithKline LLC Dérivés de l'azabicyclo[3.2.1]octyle pour leur utilisation dans le traitement du VIH
BR112012024522A2 (pt) 2010-04-02 2017-08-08 Phivco 1 Llc combinação, uso de uma combinação, composição farmacêutica, forma de dosagem única , kit, e, método para tratar um distúrbio
JP2014518610A (ja) 2011-03-09 2014-08-07 リチャード ジー． ペステル 前立腺癌細胞系、遺伝子シグネチャー及びその使用
US20140271680A1 (en) 2011-08-12 2014-09-18 Universite Paris-Est Creteil Val De Marne Methods and pharmaceutical compositions for treatment of pulmonary hypertension
WO2013173312A1 (fr) * 2012-05-14 2013-11-21 Pestell Richard G Utilisation de modulateurs de ccr5 dans le traitement du cancer
WO2014102594A2 (fr) 2012-12-27 2014-07-03 Purdue Pharma L.P. Composés de pipéridine de type benzimidazole substitué et leurs utilisations

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9125900D0 (en) 1991-12-05 1992-02-05 Wyeth John & Brother Ltd Piperazine derivatives
PH30413A (en) 1992-03-26 1997-05-09 Boehringer Ingelheim Italia Crystalline forms of endo-2,3-dihydro-n-(8-methyl)-8-azabicyclo-(3,2,1)oct-3-yl)-2-oxo-1h-benzimidazole-1-carboxamides
GB9310713D0 (en) * 1993-05-24 1993-07-07 Zeneca Ltd Aryl substituted heterocycles
FR2728166A1 (fr) 1994-12-19 1996-06-21 Oreal Composition topique contenant un antagoniste de substance p
SK1296A3 (en) * 1995-01-04 1996-08-07 Bayer Ag Acyled pseudopeptides with trifluoromethyl-substituted 2-azabicyklooctane, manufacturing process thereof and medicaments containing these substances
GB9502644D0 (en) * 1995-02-10 1995-03-29 Zeneca Ltd Heterocyclic derivatives
GB9523526D0 (en) * 1995-11-17 1996-01-17 Zeneca Ltd Therapeutic compounds
WO1997024325A1 (fr) * 1995-12-28 1997-07-10 Takeda Chemical Industries, Ltd. DERIVES DE DIPHENYLMETHANE UTILISES COMME ANTAGONISTES DU RECEPTEUR MIP-1α/RANTES
JP3455229B2 (ja) * 1996-03-29 2003-10-14 ファイザー インク． ６―フェニルピリジル―２―アミン誘導体
CA2259927A1 (fr) * 1996-07-12 1998-01-22 Leukosite, Inc. Antagonistes des recepteurs de la chemokine et procedes d'utilisation de ces derniers
US6323206B1 (en) * 1996-07-12 2001-11-27 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
CA2261633A1 (fr) * 1996-07-29 1998-02-05 Banyu Pharmaceutical Co., Ltd. Antagonistes de recepteurs de chemokines
AU5803398A (en) 1996-12-13 1998-07-03 Merck & Co., Inc. Spiro-substituted azacycles as modulators of chemokine receptor activity
WO1998025604A1 (fr) 1996-12-13 1998-06-18 Merck & Co., Inc. Azacycles a spiro-substitution utilises en tant que modulateurs de l'activite du recepteur de la chimiokine
WO1998025617A1 (fr) 1996-12-13 1998-06-18 Merck & Co., Inc. Arylpiperazines substituees utilisees comme modulateurs de l'activite du recepteur de la chemokine
JP2001508798A (ja) 1997-01-21 2001-07-03 メルク エンド カンパニー インコーポレーテッド ケモカインレセプター活性のモジュレーターとしての３，３−二置換ピペリジン類
JP2002510327A (ja) 1997-07-25 2002-04-02 メルク エンド カンパニー インコーポレーテッド 環状アミンケモカイン受容体活性調節剤
IL125658A0 (en) * 1997-08-18 1999-04-11 Hoffmann La Roche Ccr-3 receptor antagonists
JP2001526178A (ja) 1997-08-28 2001-12-18 メルク エンド カムパニー インコーポレーテッド ピロリジン系およびピペリジン系ケモカイン受容体活性調節剤
AR013669A1 (es) * 1997-10-07 2001-01-10 Smithkline Beecham Corp Compuestos y metodos
AU2335699A (en) * 1998-01-21 1999-08-09 Kyowa Hakko Kogyo Co. Ltd. Chemokine receptor antagonists and methods of use therefor

Also Published As

Publication number Publication date
NO20013183L (no) 2001-08-08
AU763644B2 (en) 2003-07-31
EA004988B1 (ru) 2004-10-28
HRP20010468B1 (en) 2012-06-30
HRP20120132A2 (hr) 2012-03-31
BG105721A (en) 2002-02-28
NO330677B1 (no) 2011-06-06
EP1140085A1 (fr) 2001-10-10
KR20010089701A (ko) 2001-10-08
BR9917007A (pt) 2001-10-30
BG65448B1 (bg) 2008-08-29
PL201875B1 (pl) 2009-05-29
GEP20033131B (en) 2003-12-25
DZ3326A1 (fr) 2005-05-29
HK1039902A1 (zh) 2002-05-17
TW577888B (en) 2004-03-01
IS5944A (is) 2001-05-15
AP2001002186A0 (en) 2001-06-30
NZ511794A (en) 2003-10-31
CZ300926B6 (cs) 2009-09-09
ME00513B (fr) 2011-10-10
ATE505190T1 (de) 2011-04-15
PL349495A1 (en) 2002-07-29
CO5300387A1 (es) 2003-07-31
SK8752001A3 (en) 2003-02-04
CU23344A3 (es) 2009-02-20
PA8487201A1 (es) 2002-02-21
EG24400A (en) 2009-04-29
CR6392A (es) 2006-08-09
JP3602795B2 (ja) 2004-12-15
DE69943352D1 (de) 2011-05-26
JP2002533393A (ja) 2002-10-08
HRP20010468A2 (en) 2003-02-28
CA2350073A1 (fr) 2000-07-06
NO20013183D0 (no) 2001-06-25
HRP20120132B1 (hr) 2018-01-26
KR100425612B1 (ko) 2004-04-01
EA200100589A1 (ru) 2002-02-28
TR200101793T2 (tr) 2001-12-21
DZ2979A1 (fr) 2005-01-30
TNSN99252A1 (fr) 2005-11-10
EE200100345A (et) 2002-12-16
PE20001420A1 (es) 2000-12-18
IL143512A (en) 2013-06-27
EE05170B1 (et) 2009-06-15
BRPI9917007B8 (pt) 2021-05-25
HUP0104795A3 (en) 2002-05-28
GC0000117A (en) 2005-06-29
AP1697A (en) 2006-12-22
CZ20012298A3 (cs) 2002-09-11
US6586430B1 (en) 2003-07-01
OA11735A (en) 2005-05-12
WO2000038680A1 (fr) 2000-07-06
ID28965A (id) 2001-07-19
YU38801A (sh) 2005-06-10
HUP0104795A2 (hu) 2002-04-29
SK287020B6 (sk) 2009-09-07
AU1675100A (en) 2000-07-31
CA2350073C (fr) 2007-04-17
UA72750C2 (en) 2005-04-15
PT1140085E (pt) 2011-06-16
HU228754B1 (en) 2013-05-28
HRP20120132A8 (hr) 2017-11-03
BRPI9917007B1 (pt) 2016-07-26
CY1111504T1 (el) 2015-08-05
DK1140085T3 (da) 2011-06-27
EP1140085B1 (fr) 2011-04-13
SI1140085T1 (sl) 2011-08-31
IL143512A0 (en) 2002-04-21
AR024233A1 (es) 2002-09-25
CN1331591A (zh) 2002-01-16
RS51701B (sr) 2011-10-31
CR9879A (es) 2008-06-20

Similar Documents

Publication Publication Date Title
MA26714A1 (fr) Composes nouveaux modulateurs de chimiokine ccr5 et compositions pharmaceutiques les contenant
MA26715A1 (fr) Composes chimiques nouveaux modulateurs de ccr5, et compositions pharmaceutiques les contenant.
DZ2086A1 (fr) Benzylaminopipéridines substituées et compositionspharmaceutiques les contenant.
MA26537A1 (fr) Derives de 2-aminopyridine nouveaux et compositions pharmaceutiques les contenant.
DZ2461A1 (fr) Dérivés d&#39;arylkylamines nouveaux et composition pharmaceutiques les contenant.
DZ2745A1 (fr) BicycloÄ2.2.1Üheptanes nouveaux procédé pour leur préparation et compositions pharmaceutiques les contenant.
MA26553A1 (fr) Alpha-aryl-n-alkylnitrones et compositions pharmaceutiques contenant ceux-la
DZ2361A1 (fr) Dérivés de 6-phénylpyridyl-2-amine et compositionspharmaceutiques les contenant
DE69634053D1 (de) Oral anzuwendende Arzneizusammensetzung enthaltend 2-Methyl-thienobenzodiazepin
FR2736641B1 (fr) Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2730491B1 (fr) Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2736638B1 (fr) Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2730492B1 (fr) Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent
MA26412A1 (fr) Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
PT1105123E (pt) Composicoes farmaceuticas contendo inibidores da lipase e quitosano
FR04C0032I2 (fr) Nouveaux derives de quinuclidine et composition pharmaceutique les contenant
DZ2494A1 (fr) Composition pharmaceutique d&#39;oméprazole.
MA23895A1 (fr) Amides therapeutiques et compositions les contenant
DE69618587T2 (de) Chinazoline und pharmazeutische zusammensetzungen
IL119466A0 (en) Thrombin inhibitors their preparation and pharmaceutical compositions containing them
NO20002165D0 (no) Farmasøytiske blandinger inneholdende cyklodekstriner og taksoider
FR2807038B1 (fr) Nouveaux derives d&#39;indolin-2-one, leur preparation et les compositions pharmaceutiques les contenant
FR2751969B1 (fr) Composes activateurs du canal cftr, et compositions pharmaceutiques les contenant
IL117815A0 (en) Ascomycins their preparation and pharmaceutical compositions containing them
FR2796380B3 (fr) Nouveaux derives d&#39;aminothiazoles, leur preparation et les compositions pharmaceutiques les contenant